AbCellera And Lilly Expand Collaboration To Develop Antibody Medicines
AbCellera And Lilly Expand Collaboration To Develop Antibody Medicines
AbCellera (NASDAQ:ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera's COVID-19 antibody program.
AbCellera（纳斯达克：ABCL）今日宣布，已经扩大了与Eli Lilly and Company（Lilly）现有的合作，以发现用于免疫学、心血管疾病和神经科学计划的治疗性抗体。该扩展建立在自2020年3月建立的成功研究合作的基础之上，该合作包括Lilly选定的八个全新计划和AbCellera的COVID-19抗体计划的独家许可证。
AbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the U.S. Food and Drug Administration for two COVID-19 antibody therapies co-developed by the companies.
AbCellera已经推进了原始协议下的所有八个计划，并且许可计划通过该公司共同开发的两种COVID-19抗体疗法获得了美国食品和药品管理局的紧急使用授权。
